Loading
Hepatitis B/C, HIV screening, vascular access infections, and the CDC bundle approach — the updated evidence for dialysis infection control programs.
Evidence reviewed & updated: 2026-07 — reflects the latest published trials and guidelines.
Dialysis patients face uniquely high infection risk: access-related bloodstream infections, hepatitis B/C transmission (historically), and multidrug-resistant organisms. The 2026 approach: CDC-derived prevention bundles (vascular access care, hand hygiene, environmental disinfection, vaccination), rigorous viral screening (HBsAg, anti-HCV, HIV annually), and data-driven surveillance with benchmarked rates.
CDC/NKF recommendation: all patients screened at dialysis initiation and annually: HBsAg, anti-HBs, anti-HCV, and HIV (with consent). Vaccinated patients: confirm anti-HBs >10 mIU/mL. HBV-susceptible: vaccinate with double-dose vaccine (40µg Engerix-B at 0,1,2,6 months — the dialysis-specific schedule).
HBV-positive patients: dialyze in a SEPARATE ROOM with dedicated machines and staff (strictest isolation requirement — CDC). HCV-positive: designated area with dedicated machines; staff assignment preferred when feasible (per 2001 CDC recommendations still operative).
New HCV treatments changed the landscape: DAA therapy (sofosbuvir-based) can CURE HCV in dialysis patients (sofosbuvir + daclatasvir/velpatasvir, dose-adjusted) — screening now leads to treatment rather than lifelong isolation for many.
The BSI prevention bundle (CDC-derived): (1) catheter hub disinfection before every access (chlorhexidine or alcohol scrub 15 seconds), (2) aseptic technique with full barrier precautions during catheter connection/disconnection, (3) hand hygiene before and after access, (4) skin antisepsis with 2% chlorhexidine, (5) access site inspection before cannulation, (6) dressings: transparent, changed at each session.
Catheter care: antibiotic locks only for documented infections (NOT prophylaxis — KDOQI 2019). Dedicated catheter connectors (Tego) reduce hub contamination. Replace transparent dressings per protocol; wet/soiled dressings changed immediately.
The single most effective BSI reduction strategy: REDUCE CATHETER USE. Every CVC day carries ~3-10x the BSI risk of AVF. Catheter reduction programs (access planning, AVF maturation surveillance) are the highest-leverage infection control intervention (see AVF vs AVG vs CVC topic).
Metrics: (1) BSI rate per 100 patient-months by access type (catheter vs AVF/AVG — report separately), (2) % patients dialyzing with CVC (target <30%, Fistula First benchmark), (3) viral seroconversion rate (target zero), (4) MRSA/VRE prevalence, (5) infection-related hospitalization rate.
CDC's NHSN dialysis event reporting (utilized globally) defines: IV antimicrobial start (proxy for BSI), positive blood culture, and access infection. Indian centers can adopt this framework for internal benchmarking even without NHSN membership.
Surveillance data drives action: monthly review of BSI rates by access type identifies problem areas (e.g., one nurse's technique, one catheter cohort). Facilities with active surveillance reduce BSI by 40-60% within a year (published quality improvement data).
Program essentials: (1) written infection control manual (NABH HIC chapter compliance), (2) infection control nurse (or designee) with defined responsibilities, (3) monthly surveillance with documented review, (4) staff immunization records (HBV — 96% of staff should have titers >10), (5) annual staff training with competency assessment.
Emerging focus: multidrug-resistant organisms (ESBL, carbapenem-resistant Enterobacterales) in dialysis units — screening on admission from hospitals, isolation precautions, antibiotic stewardship.
Digital tools: EMR-integrated infection surveillance (ZuvFlo's infection module) auto-tracks serology dates, vaccination schedules, BSI events by access, and generates the monthly surveillance report — the documentation backbone of an NABH-ready program.
Advertisement
The access hierarchy is clear: AV fistula > AV graft > catheter. AVF has the lowest infection and thrombosis rates and l...
Learn morePeritonitis remains the Achilles heel of PD programs. The ISPD 2022 guidelines set the framework: prevention bundles (tr...
Learn moreBoth hemodialysis (HD) and peritoneal dialysis (PD) provide comparable survival outcomes in most patient populations. Th...
Learn moreZuvFlo is ready to integrate with your facility to streamline operations, automate compliance, and deliver better patient care.
No credit card required • Setup in under 2 hours • Cancel anytime
Advertisement
This content is a general reference, not medical advice, a diagnosis, or a treatment plan. Do not change your diet, fluids, medicines, or dialysis plan without your nephrologist or renal dietitian. Individual recommendations depend on your labs, medications, conditions, and care plan.